Pirdoğan Aydın Efruz, Alsaadoni Hani, Gökovalı Beğenen Azra, Akil Özer Ömer, Oğuz Karamustafalıoğlu Kayıhan, Pençe Sadrettin
Department of Psychiatry, University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital, İstanbul, Turkey.
Department of Medical Biology, University of Health Sciences of Medicine, İstanbul, Turkey.
Psychiatry Clin Psychopharmacol. 2022 Jun 1;32(2):98-106. doi: 10.5152/pcp.2022.22391. eCollection 2022 Jun.
Obsessive-compulsive disorder is a psychiatric disorder with different clinical manifestations caused by the interaction of genetic and environmental factors. Recently, it has been shown that microRNAs play a role in the pathogenesis of some psychiatric diseases. We aimed to compare the expression levels of microRNAs between obsessive-compulsive disorder patients and healthy controls and investigate the association between miRNA expression levels and treatment resistance.
Twelve miRNA expression levels in venous blood of 100 obsessive-compulsive disorder patients and 50 healthy controls were detected by real-time polymerase chain reaction. Patients were assessed using the Hamilton Depression Rating Scale, Yale-Brown Obsessive-Compulsive Scale, and Yale-Brown Obsessive-Compulsive Symptom Checklist. Each patient was scheduled for a monthly follow-up for a minimum 6-month-period after serotonin receptor inhibitor treatments were initiated.
We found that miR-26a-5p ( < .001), miR-21-3p ( < .001), miR-219a-1-3p ( = .016), miR-106b-5p ( = .039), miR-6740-5p ( = .020), miR-320a ( = .001), miR-22-3p, and miR-16b-5p ( = .010) expression levels were statistically higher in obsessive-compulsive disorder patients than healthy controls; miR-135a-5p ( < .001) and miR-129-6b-5p ( < .001) expression levels were statistically lower. Also, it was determined that increased miR-106b-5p levels were associated with treatment-resistance ( = .020) and there was a negative correlation between miR-374b-3p and disease severity ( = .042).
In obsessive-compulsive disorder, there may be a potential value in the relationship between various miRNA expression levels and treatment resistance and disease severity, and future studies may be beneficial.
强迫症是一种由遗传和环境因素相互作用导致临床表现各异的精神疾病。最近研究表明，微小RNA在某些精神疾病的发病机制中发挥作用。我们旨在比较强迫症患者与健康对照者之间微小RNA的表达水平，并研究微小RNA表达水平与治疗抵抗之间的关联。
采用实时聚合酶链反应检测100例强迫症患者和50例健康对照者静脉血中12种微小RNA的表达水平。使用汉密尔顿抑郁量表、耶鲁-布朗强迫症量表和耶鲁-布朗强迫症症状清单对患者进行评估。在开始使用5-羟色胺受体抑制剂治疗后，每位患者每月进行一次随访，为期至少6个月。
我们发现，强迫症患者中miR-26a-5p（<.001）、miR-21-3p（<.001）、miR-219a-1-3p（=.016）、miR-106b-5p（=.039）、miR-6740-5p（=.020）、miR-320a（<.001）、miR-22-3p和miR-16b-5p（=.010）的表达水平在统计学上高于健康对照者；miR-135a-5p（<.001）和miR-129-6b-5p（<.001）的表达水平在统计学上较低。此外，确定miR-106b-5p水平升高与治疗抵抗相关（=.020），且miR-374b-3p与疾病严重程度之间存在负相关（=.042）。
在强迫症中，各种微小RNA表达水平与治疗抵抗及疾病严重程度之间的关系可能具有潜在价值，未来的研究可能会有所助益。
